DUBLIN–(BUSINESS WIRE)–The “Migraine – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Migraine (Central Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 11, 15, 11, 1, 31, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. (Read more…)
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Migraine – Overview
• Migraine – Therapeutics Development
• Migraine – Therapeutics Assessment
• Migraine – Companies Involved in Therapeutics Development
• Migraine – Drug Profiles
• Migraine – Dormant Projects
• Migraine – Discontinued Products
• Migraine – Product Development Milestones
• Appendix

Companies Mentioned

• 4P Therapeutics LLC
• Achelios Therapeutics Inc
• Acorda Therapeutics Inc
• AgoneX Biopharmaceuticals Inc
• Allergan Plc
• Allodynic Therapeutics LLC
• Amgen Inc
• AOBiome LLC
• Aptarion biotech AG
• Asarina Pharma AB
• Astrocyte Pharmaceuticals Inc
• Avanir Pharmaceuticals Inc
• Axsome Therapeutics Inc
• Better Life Pharmaceuticals Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Blackthorn Therapeutics Inc
• Cerecin Inc
• CerSci Therapeutics Inc
• Charleston Laboratories Inc
• Citragen Pharmaceuticals Inc
• Corium, Inc.
• Crossject SA
• Curatis AG
• CURx Pharmaceuticals Inc
• DelNova Inc
• Eli Lilly and Co
• Epalex Corp
• Exxel Pharma Inc
• H. Lundbeck AS
• Impel NeuroPharma Inc
• InKemia IUCT Group SA
• InStar Technologies AS
• IntelGenx Corp
• Invisio Ltd
• Ionis Pharmaceuticals Inc
• Klaria Pharma Holding AB
• Lateral Pharma Pty Ltd
• Living Cell Technologies Ltd
• MannKind Corp
• Medytox Inc
• Merck & Co Inc
• NAL Pharmaceuticals Ltd
• NeurAxon Pharma Inc
• NutriBand Inc
• OWP Pharmaceuticals Inc
• Panaxia Pharmaceutical Industries Ltd
• Pharmaleads SA
• Pharmnovo AB
• Pherin Pharmaceuticals Inc
• Promius Pharma LLC
• Qingdao Chia Tai Haier Pharmaceutical Co Ltd
• RAFT Pharmaceuticals
• Revance Therapeutics Inc
• Satsuma Pharmaceuticals Inc
• Seurat Therapeutics Inc
• Shanghai Junshi Bioscience Co Ltd
• Shin Nippon Biomedical Laboratories Ltd
• Sorrento Therapeutics Inc
• Sosei Heptares
• Suda Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd
• Trevena Inc
• Trigemina Inc
• TrioxBio Inc
• United Neuroscience Ltd
• Xenon Pharmaceuticals Inc
• Xoc Pharmaceuticals Inc
• Zosano Pharma Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8xrh8k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Migraine – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Migraine (Central Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 11, 15, 11, 1, 31, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. (Read more…)
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Migraine – Overview
• Migraine – Therapeutics Development
• Migraine – Therapeutics Assessment
• Migraine – Companies Involved in Therapeutics Development
• Migraine – Drug Profiles
• Migraine – Dormant Projects
• Migraine – Discontinued Products
• Migraine – Product Development Milestones
• Appendix

Companies Mentioned

• 4P Therapeutics LLC
• Achelios Therapeutics Inc
• Acorda Therapeutics Inc
• AgoneX Biopharmaceuticals Inc
• Allergan Plc
• Allodynic Therapeutics LLC
• Amgen Inc
• AOBiome LLC
• Aptarion biotech AG
• Asarina Pharma AB
• Astrocyte Pharmaceuticals Inc
• Avanir Pharmaceuticals Inc
• Axsome Therapeutics Inc
• Better Life Pharmaceuticals Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Blackthorn Therapeutics Inc
• Cerecin Inc
• CerSci Therapeutics Inc
• Charleston Laboratories Inc
• Citragen Pharmaceuticals Inc
• Corium, Inc.
• Crossject SA
• Curatis AG
• CURx Pharmaceuticals Inc
• DelNova Inc
• Eli Lilly and Co
• Epalex Corp
• Exxel Pharma Inc
• H. Lundbeck AS
• Impel NeuroPharma Inc
• InKemia IUCT Group SA
• InStar Technologies AS
• IntelGenx Corp
• Invisio Ltd
• Ionis Pharmaceuticals Inc
• Klaria Pharma Holding AB
• Lateral Pharma Pty Ltd
• Living Cell Technologies Ltd
• MannKind Corp
• Medytox Inc
• Merck & Co Inc
• NAL Pharmaceuticals Ltd
• NeurAxon Pharma Inc
• NutriBand Inc
• OWP Pharmaceuticals Inc
• Panaxia Pharmaceutical Industries Ltd
• Pharmaleads SA
• Pharmnovo AB
• Pherin Pharmaceuticals Inc
• Promius Pharma LLC
• Qingdao Chia Tai Haier Pharmaceutical Co Ltd
• RAFT Pharmaceuticals
• Revance Therapeutics Inc
• Satsuma Pharmaceuticals Inc
• Seurat Therapeutics Inc
• Shanghai Junshi Bioscience Co Ltd
• Shin Nippon Biomedical Laboratories Ltd
• Sorrento Therapeutics Inc
• Sosei Heptares
• Suda Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd
• Trevena Inc
• Trigemina Inc
• TrioxBio Inc
• United Neuroscience Ltd
• Xenon Pharmaceuticals Inc
• Xoc Pharmaceuticals Inc
• Zosano Pharma Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8xrh8k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Migraine – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Migraine (Central Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 11, 15, 11, 1, 31, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. (Read more…)
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Migraine – Overview
• Migraine – Therapeutics Development
• Migraine – Therapeutics Assessment
• Migraine – Companies Involved in Therapeutics Development
• Migraine – Drug Profiles
• Migraine – Dormant Projects
• Migraine – Discontinued Products
• Migraine – Product Development Milestones
• Appendix

Companies Mentioned

• 4P Therapeutics LLC
• Achelios Therapeutics Inc
• Acorda Therapeutics Inc
• AgoneX Biopharmaceuticals Inc
• Allergan Plc
• Allodynic Therapeutics LLC
• Amgen Inc
• AOBiome LLC
• Aptarion biotech AG
• Asarina Pharma AB
• Astrocyte Pharmaceuticals Inc
• Avanir Pharmaceuticals Inc
• Axsome Therapeutics Inc
• Better Life Pharmaceuticals Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Blackthorn Therapeutics Inc
• Cerecin Inc
• CerSci Therapeutics Inc
• Charleston Laboratories Inc
• Citragen Pharmaceuticals Inc
• Corium, Inc.
• Crossject SA
• Curatis AG
• CURx Pharmaceuticals Inc
• DelNova Inc
• Eli Lilly and Co
• Epalex Corp
• Exxel Pharma Inc
• H. Lundbeck AS
• Impel NeuroPharma Inc
• InKemia IUCT Group SA
• InStar Technologies AS
• IntelGenx Corp
• Invisio Ltd
• Ionis Pharmaceuticals Inc
• Klaria Pharma Holding AB
• Lateral Pharma Pty Ltd
• Living Cell Technologies Ltd
• MannKind Corp
• Medytox Inc
• Merck & Co Inc
• NAL Pharmaceuticals Ltd
• NeurAxon Pharma Inc
• NutriBand Inc
• OWP Pharmaceuticals Inc
• Panaxia Pharmaceutical Industries Ltd
• Pharmaleads SA
• Pharmnovo AB
• Pherin Pharmaceuticals Inc
• Promius Pharma LLC
• Qingdao Chia Tai Haier Pharmaceutical Co Ltd
• RAFT Pharmaceuticals
• Revance Therapeutics Inc
• Satsuma Pharmaceuticals Inc
• Seurat Therapeutics Inc
• Shanghai Junshi Bioscience Co Ltd
• Shin Nippon Biomedical Laboratories Ltd
• Sorrento Therapeutics Inc
• Sosei Heptares
• Suda Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd
• Trevena Inc
• Trigemina Inc
• TrioxBio Inc
• United Neuroscience Ltd
• Xenon Pharmaceuticals Inc
• Xoc Pharmaceuticals Inc
• Zosano Pharma Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8xrh8k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Migraine – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Migraine (Central Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 11, 15, 11, 1, 31, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. (Read more…)
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Migraine – Overview
• Migraine – Therapeutics Development
• Migraine – Therapeutics Assessment
• Migraine – Companies Involved in Therapeutics Development
• Migraine – Drug Profiles
• Migraine – Dormant Projects
• Migraine – Discontinued Products
• Migraine – Product Development Milestones
• Appendix

Companies Mentioned

• 4P Therapeutics LLC
• Achelios Therapeutics Inc
• Acorda Therapeutics Inc
• AgoneX Biopharmaceuticals Inc
• Allergan Plc
• Allodynic Therapeutics LLC
• Amgen Inc
• AOBiome LLC
• Aptarion biotech AG
• Asarina Pharma AB
• Astrocyte Pharmaceuticals Inc
• Avanir Pharmaceuticals Inc
• Axsome Therapeutics Inc
• Better Life Pharmaceuticals Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Blackthorn Therapeutics Inc
• Cerecin Inc
• CerSci Therapeutics Inc
• Charleston Laboratories Inc
• Citragen Pharmaceuticals Inc
• Corium, Inc.
• Crossject SA
• Curatis AG
• CURx Pharmaceuticals Inc
• DelNova Inc
• Eli Lilly and Co
• Epalex Corp
• Exxel Pharma Inc
• H. Lundbeck AS
• Impel NeuroPharma Inc
• InKemia IUCT Group SA
• InStar Technologies AS
• IntelGenx Corp
• Invisio Ltd
• Ionis Pharmaceuticals Inc
• Klaria Pharma Holding AB
• Lateral Pharma Pty Ltd
• Living Cell Technologies Ltd
• MannKind Corp
• Medytox Inc
• Merck & Co Inc
• NAL Pharmaceuticals Ltd
• NeurAxon Pharma Inc
• NutriBand Inc
• OWP Pharmaceuticals Inc
• Panaxia Pharmaceutical Industries Ltd
• Pharmaleads SA
• Pharmnovo AB
• Pherin Pharmaceuticals Inc
• Promius Pharma LLC
• Qingdao Chia Tai Haier Pharmaceutical Co Ltd
• RAFT Pharmaceuticals
• Revance Therapeutics Inc
• Satsuma Pharmaceuticals Inc
• Seurat Therapeutics Inc
• Shanghai Junshi Bioscience Co Ltd
• Shin Nippon Biomedical Laboratories Ltd
• Sorrento Therapeutics Inc
• Sosei Heptares
• Suda Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd
• Trevena Inc
• Trigemina Inc
• TrioxBio Inc
• United Neuroscience Ltd
• Xenon Pharmaceuticals Inc
• Xoc Pharmaceuticals Inc
• Zosano Pharma Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8xrh8k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Migraine – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Migraine (Central Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 11, 15, 11, 1, 31, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. (Read more…)
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Migraine – Overview
• Migraine – Therapeutics Development
• Migraine – Therapeutics Assessment
• Migraine – Companies Involved in Therapeutics Development
• Migraine – Drug Profiles
• Migraine – Dormant Projects
• Migraine – Discontinued Products
• Migraine – Product Development Milestones
• Appendix

Companies Mentioned

• 4P Therapeutics LLC
• Achelios Therapeutics Inc
• Acorda Therapeutics Inc
• AgoneX Biopharmaceuticals Inc
• Allergan Plc
• Allodynic Therapeutics LLC
• Amgen Inc
• AOBiome LLC
• Aptarion biotech AG
• Asarina Pharma AB
• Astrocyte Pharmaceuticals Inc
• Avanir Pharmaceuticals Inc
• Axsome Therapeutics Inc
• Better Life Pharmaceuticals Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Blackthorn Therapeutics Inc
• Cerecin Inc
• CerSci Therapeutics Inc
• Charleston Laboratories Inc
• Citragen Pharmaceuticals Inc
• Corium, Inc.
• Crossject SA
• Curatis AG
• CURx Pharmaceuticals Inc
• DelNova Inc
• Eli Lilly and Co
• Epalex Corp
• Exxel Pharma Inc
• H. Lundbeck AS
• Impel NeuroPharma Inc
• InKemia IUCT Group SA
• InStar Technologies AS
• IntelGenx Corp
• Invisio Ltd
• Ionis Pharmaceuticals Inc
• Klaria Pharma Holding AB
• Lateral Pharma Pty Ltd
• Living Cell Technologies Ltd
• MannKind Corp
• Medytox Inc
• Merck & Co Inc
• NAL Pharmaceuticals Ltd
• NeurAxon Pharma Inc
• NutriBand Inc
• OWP Pharmaceuticals Inc
• Panaxia Pharmaceutical Industries Ltd
• Pharmaleads SA
• Pharmnovo AB
• Pherin Pharmaceuticals Inc
• Promius Pharma LLC
• Qingdao Chia Tai Haier Pharmaceutical Co Ltd
• RAFT Pharmaceuticals
• Revance Therapeutics Inc
• Satsuma Pharmaceuticals Inc
• Seurat Therapeutics Inc
• Shanghai Junshi Bioscience Co Ltd
• Shin Nippon Biomedical Laboratories Ltd
• Sorrento Therapeutics Inc
• Sosei Heptares
• Suda Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd
• Trevena Inc
• Trigemina Inc
• TrioxBio Inc
• United Neuroscience Ltd
• Xenon Pharmaceuticals Inc
• Xoc Pharmaceuticals Inc
• Zosano Pharma Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8xrh8k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Migraine – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Migraine (Central Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 11, 15, 11, 1, 31, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. (Read more…)
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Migraine – Overview
• Migraine – Therapeutics Development
• Migraine – Therapeutics Assessment
• Migraine – Companies Involved in Therapeutics Development
• Migraine – Drug Profiles
• Migraine – Dormant Projects
• Migraine – Discontinued Products
• Migraine – Product Development Milestones
• Appendix

Companies Mentioned

• 4P Therapeutics LLC
• Achelios Therapeutics Inc
• Acorda Therapeutics Inc
• AgoneX Biopharmaceuticals Inc
• Allergan Plc
• Allodynic Therapeutics LLC
• Amgen Inc
• AOBiome LLC
• Aptarion biotech AG
• Asarina Pharma AB
• Astrocyte Pharmaceuticals Inc
• Avanir Pharmaceuticals Inc
• Axsome Therapeutics Inc
• Better Life Pharmaceuticals Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Blackthorn Therapeutics Inc
• Cerecin Inc
• CerSci Therapeutics Inc
• Charleston Laboratories Inc
• Citragen Pharmaceuticals Inc
• Corium, Inc.
• Crossject SA
• Curatis AG
• CURx Pharmaceuticals Inc
• DelNova Inc
• Eli Lilly and Co
• Epalex Corp
• Exxel Pharma Inc
• H. Lundbeck AS
• Impel NeuroPharma Inc
• InKemia IUCT Group SA
• InStar Technologies AS
• IntelGenx Corp
• Invisio Ltd
• Ionis Pharmaceuticals Inc
• Klaria Pharma Holding AB
• Lateral Pharma Pty Ltd
• Living Cell Technologies Ltd
• MannKind Corp
• Medytox Inc
• Merck & Co Inc
• NAL Pharmaceuticals Ltd
• NeurAxon Pharma Inc
• NutriBand Inc
• OWP Pharmaceuticals Inc
• Panaxia Pharmaceutical Industries Ltd
• Pharmaleads SA
• Pharmnovo AB
• Pherin Pharmaceuticals Inc
• Promius Pharma LLC
• Qingdao Chia Tai Haier Pharmaceutical Co Ltd
• RAFT Pharmaceuticals
• Revance Therapeutics Inc
• Satsuma Pharmaceuticals Inc
• Seurat Therapeutics Inc
• Shanghai Junshi Bioscience Co Ltd
• Shin Nippon Biomedical Laboratories Ltd
• Sorrento Therapeutics Inc
• Sosei Heptares
• Suda Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd
• Trevena Inc
• Trigemina Inc
• TrioxBio Inc
• United Neuroscience Ltd
• Xenon Pharmaceuticals Inc
• Xoc Pharmaceuticals Inc
• Zosano Pharma Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8xrh8k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900